We are monitoring the impact of COVID-19 on Preventive Vaccines Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 135
Share on
Share on

Global Preventive Vaccines Market Size, Share, Trends, COVID-19 impact, Growth Analysis Report - Segmented By Vaccine Type (Live, Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, and Recombinant Vector Vaccines), End User and Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 135
Pages: 175

Global Preventive Vaccines Market Size (2021 to 2026)

As public healthcare-focused organizations strive to improve vaccination coverage, we expect the market to grow at a CAGR of 12.74% from 2021 to 2026. The global preventive vaccines market size is estimated to be USD 78.93 billion by 2026 from USD 43.34 billion in 2021.

Although vaccines were solely responsible for the global eradication of small polio, several vaccine-preventable diseases, such as measles and mumps, are still a threat. COVID-19 has been recently added to the list.

The vaccine market accounts for only 5% of the global pharmaceuticals market. However, recently there has been substantial growth owing to the rising incidences of cancer & HIV cases. Nevertheless, there has been rapid growth over recent years, with the vaccine market magnifying in value from USD 5 billion in 2000 to almost USD 25 billion in 2013. World Health Organization (WHO) growth estimations indicate the market may increase in value to nearly 60 billion in 2020, with the arrival of new therapeutic, preventive, and adult vaccines.

Current Industry Scenario:

The global Preventive Vaccines Market is different from any other product market. Compared to the pharmaceutical market, it is relatively small, although growing at a fast rate. There are presently close to 120 new vaccines in the pipeline of various multinational companies across the globe set to hit the market in the next few years. The global Preventive Vaccines Market is relatively concentrated on both the supply and demand sides. It is highly regulated and mostly dependent on public purchasers and donor policies. It has very distinct features that increase the complexity of assessing and understanding pricing and procurement in their context.

  • Over 200+ vaccines are presently being evaluated in the clinical stages of development.
  • Foreseeing a lucrative growth in this domain, several private and public investors have invested over USD 10 billion in vaccine development initiatives across 175 countries from 2015 to 2020.

MARKET DRIVERS:

The growing infectious disease burden is expected to contribute significantly to the growth of the Preventive Vaccines Market.

  • The concept of vaccination has dramatically reduced the mortality, morbidity, and complications associated with a wide range of infectious diseases.
  • More than 1400 clinical trials evaluate various types of preventive vaccines have been registered, indicating the rapid pace of development in this field.
  • Over 1.5 Million children under the age of 5 love their lives to vaccine-preventable diseases every year.
  • By WHO, more than 1400 epidemic events tracked in 172 countries between 2011 and 2018.
  • Approximate 3 million deaths are preventable with effective immunizations every year.  

Growing investments by the key market players and increasing funding from the governments for vaccine developments propel global market growth.

Furthermore, the rising prevalence of the disease, technological advancements to decrease the new vaccine development time, and initiatives by NGOs also contribute well to the Preventive Vaccines Market growth. 

MARKET RESTRAINTS:

However, massive capital expenditures and stringent regulatory policies, high costs associated with treatment are few factors inhibiting the growth of the global Preventive Vaccines Market. The lack of skilled and efficient labor required for manufacturing the vaccine among the pharmaceutical and biotechnology companies is to curb the market growth rate. The high cost of the raw materials required in the laboratories to develop a vaccine impedes the market demand. 

Impact of COVID-19 on the global preventive vaccines market:

World Health Organization has announced COVID-19 as an emergency health issue. The COVID-19 has positive vibes in the vaccine market. The World Health Organization (WHO) declared the coronavirus epidemic a public health emergency in January 2020. The COVID-19 pandemic has posed several major problems, impacting public health and economic processes, socio-cultural trends, etc. Many countries are starting to introduce COVID-19 vaccines, bringing the fight against the global pandemic new hope.

Owing to increasing healthcare spending, evolving vaccine technologies, and increased demand for preventive vaccines, especially new COVID-19 vaccines, the market has demand during this pandemic. Scientists worldwide are currently conducting research, sharing knowledge, establishing laboratory capability in developing countries, and establishing global monitoring networks to prevent and monitor their spread by preventive vaccines. The Preventive vaccine industry is positive about the COVID-19. Pharmaceutical and biotechnology firms are working together to develop and manufacture the vaccine. The global preventive vaccines market is expanding due to the growing prevalence of infectious diseases, advanced vaccine research technologies, increased support from government and foreign organizations, and increased awareness about preventive care. Pfizer Inc., Sanofi is among the key companies participating in the development of the COVID-19 vaccine. By considering all these factors, the Preventive Vaccine Market has positive growth due to this pandemic.

The pharmaceutical companies and the biotechnology industries are collaborating to innovate and manufacturing the vaccine. The market key players like Pfizer and BioNTech have made some clinical trials and have produced millions of doses. In the present situation, more research and development activities are being encouraged for COVID-19 vaccines. Scientists and experts are working continuously to develop an effective vaccine in a short period. In October 2020, the FDA approved Veklury (remdesivir), the first drug approved for treating COVID-19 patients. It is intentionally used in adults and children of 12 years and above. Key players involved in the manufacturing of the COVID-19 vaccine are Pfizer Inc., Sanofi, Johnson & Johnson Services Inc. are playing an important role in producing a vaccine for COVID-19. 

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Product Type, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

 

This research report on the global Preventive Vaccines Market has been segmented and sub-segmented based on the product type, application, and region.

Preventive Vaccines Market - By Vaccine Type:

  • Live, Attenuated Vaccines
  • Inactivated Vaccines            
  • Toxoid Vaccines   
  • Subunit Vaccines 
  • Conjugate Vaccines            
  • DNA Vaccines        
  • Recombinant Vector Vaccines

Based on the vaccine type, over 20% of the market share was occupied by Live, Attenuated Vaccines in 2019. Recombinant Vector Vaccines and Conjugate Vaccines were at the second and third position in leading the market shares. An increasing number of people who have cancer and other infectious diseases significantly influence this segment's growth. Increasing expenditure on healthcare, especially in urban areas, is promoting the development of the market. The inactivated vaccines segment is growing at a faster rate for the past few years. The rise in awareness among physicians over the availability of different vaccines for various diseases is gearing up the growth rate of the market.

Preventive Vaccines Market - By End-User:

  • Pediatric Vaccine
    • Pneumococcal
    • MMR
    • Varicella
    • Hepatitis
    • Poliovirus
    • HIB
    • Others
  • Adult Vaccines      
    • Influenza
    • Cervical Cancer
    • Hepatitis
    • Zoster
    • Others

Based on the end-user, the pneumococcal segment holds prominent shares of the market with the rise in pharmaceutical companies' investments by private and public organizations. The growing prevalence of improving treatment procedures to promote the patient's wellbeing is likely to outshine the market demand eventually.

Preventive Vaccines Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

North America leads the global preventive vaccines market due to the quick adoption of the latest technologies and innovative drugs & vaccines. The rise in pharmaceutical companies' scale and ongoing research in the biotechnology field is leveraging the demand for the Preventive Vaccines Market in North America.

Europe is next to North America is leading the highest shares of the market with the rise in the geriatric population. Growing revenue in almost every country is also a primary factor for increasing in this region.

The Asia Pacific is to have a significant growth rate in the coming years, increasing support from the government by launching reimbursement schemes in favor of ordinary people.

KEY MARKET PLAYERS:

Some of the promising companies dominating the global preventive vaccines market profiled in the report are GlaxoSmithKline PLC, Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune LLC, Pfizer, Inc., and Sanofi Pasteur.

Vaccine developers are putting in significant efforts to ensure that their candidates are clinically and commercially competent to achieve a competitive edge. Several companies have received substantial funding for their proprietary product portfolios; majorly, they are mid-sized companies based in North America. Around 70 companies in different regions worldwide claim to provide contact development, fill/finish, and regulatory support, besides manufacturing services.

RECENT MARKET HAPPENINGS:

On February 3, 2020, GSK and CEPI have recently announced that they will collaborate to develop a vaccine for the nCoV virus with the help of vaccine adjuvant platform technology developed by GSK. A more significant number of people are benefitting from the antigen-sparing effect. The primary goal of the collaboration is to develop vaccines rapidly by decreasing the dose of vaccine antigens to provide a cure for a large group of people affected by the coronavirus.

On December 31, 2019, Bavarian Nordic completed the acquisition of production and distribution rights of Encepur and RabAvert from GSK. With this deal completed, the company has expanded its product portfolios such as vaccines for monkeypox, smallpox, and other commercial products to provide growth opportunities for the company during the forecast period.

On January 8, 2020, Serum Institute of India Pvt. Ltd and Staten's serum institute have entered into a strategic partnership to intensify vaccines' development for tuberculosis. Serum Institute has developed a 10-valent pneumococcal conjugate vaccine called pneumosil, which contains CRM197, which the institute also produces under pfenex expression technology. The world health organization has prequalified the vaccine.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Analysis Design                         

                2.3 Research Phases                      

                                2.3.1 Secondary Research            

                                2.3.2 Primary Research 

                                2.3.3 Econometric Modelling     

                                2.3.4 Expert Validation  

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Vaccine Type                       

                                5.1.1 Live, Attenuated Vaccines

                                5.1.2 Inactivted Vaccines             

                                5.1.3 Toxoid Vaccines    

                                5.1.4 Subunit vaccines  

                                5.1.5 Conjugate vaccines             

                                5.1.6 DNA vaccines         

                                5.1.7 Recombinant vector vaccines          

                5.2 By End User               

                                5.2.1 Paediatric Vaccine

                                                5.2.1.1 Pneumococcal

                                                5.2.1.2 MMR

                                                5.2.1.3 Varicella

                                                5.2.1.4 Hepatitis

                                                5.2.1.5 Poliovirus

                                                5.2.1.6 HIB

                                                5.2.1.7 Others

                                5.2.2 Adult Vaccines      

                                                5.2.2.1 Influenza

                                                5.2.2.2 Cervical Cancer

                                                5.2.2.3 Hepatitis

                                                5.2.2.4 Zoster

                                                5.2.2.5 Others

6. Geographical Analysis                                              

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.2 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy           

                                6.2.6 France      

                6.3 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan        

                                6.3.5 South Korea           

                6.4 Latin America                            

                                6.4.1 Introduction           

                                6.4.2 Brazil         

                                6.4.3 Argentina

                                6.4.4 Mexico     

                6.5 Middle East & Africa               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa        

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 GlaxoSmithKline, plc.                             

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Strategic Evaluation and Operations            

                                8.1.4 Financial analysis  

                                8.1.5 Legal issues            

                                8.1.6 Recent Developments       

                                8.1.7 SWOT analysis       

                                8.1.8 Analyst View          

                8.2 Merck and Company                              

                8.3 Bavarian Nordic                        

                8.4 CSL Limited                 

                8.5 Emergent BioSolutions Inc.                  

                8.6 Novartis AG                

                8.7 Johnson and Johnson                             

                8.8 MedImmune, LLC                    

                8.9 Pfizer, Inc.                   

                8.10 Sanofi Pasteur                        

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Expert Opinions                                         

                10.1 Market Outlook                     

                10.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Preventive Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  2. Global Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  3. Global Live, Attenuated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  4. Global Inactivated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  5. Global Toxoid Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  6. Global Subunit vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  7. Global Conjugate vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  8. Global DNA vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  9. Global Recombinant vector vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  10. Global Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  11. Global Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  12. Global Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  13. Global Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  14. Global Pneumococcal Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  15. Global MMR Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  16. Global Varicella Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  17. Global Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  18. Global Poliovirus Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  19. Global HIB Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  20. Global Other Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  21. Global Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  22. Global Influenza Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  23. Global Cervical Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  24. Global Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  25. Global Zoster Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  26. Global Other Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  27. North America Preventive Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  28. North America Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  29. North America Live, Attenuated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  30. North America Inactivated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  31. North America Toxoid Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  32. North America Subunit vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  33. North America Conjugate vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  34. North America DNA vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  35. North America Recombinant vector vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  36. North America Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  37. North America Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  38. North America Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  39. North America Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  40. North America Pneumococcal Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  41. North America MMR Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  42. North America Varicella Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  43. North America Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  44. North America Poliovirus Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  45. North America HIB Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  46. North America Other Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  47. North America Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  48. North America Influenza Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  49. North America Cervical Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  50. North America Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  51. North America Zoster Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  52. North America Other Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  53. United States Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  54. United States Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  55. Canada Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  56. Canada Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  57. United States Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  58. Canada Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  59. United States Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  60. Canada Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  61. Europe Preventive Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  62. Europe Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  63. Europe Live, Attenuated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  64. Europe Inactivated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  65. Europe Toxoid Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  66. Europe Subunit vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  67. Europe Conjugate vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  68. Europe DNA vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  69. Europe Recombinant vector vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  70. Europe Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  71. Europe Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  72. Europe Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  73. Europe Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  74. Europe Pneumococcal Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  75. Europe MMR Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  76. Europe Varicella Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  77. Europe Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  78. Europe Poliovirus Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  79. Europe HIB Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  80. Europe Other Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  81. Europe Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  82. Europe Influenza Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  83. Europe Cervical Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  84. Europe Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  85. Europe Zoster Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  86. Europe Other Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  87. U.K. Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  88. U.K. Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  89. Germany Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  90. Germany Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  91. France Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  92. France Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  93. Italy Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  94. Italy Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  95. Spain Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  96. Spain Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  97. U.K. Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  98. Germany Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  99. France Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  100. Italy Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  101. Spain Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  102. U.K. Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  103. Germany Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  104. France Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  105. Italy Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  106. Spain Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  107. Asia-Pacific Preventive Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  108. Asia-Pacific Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  109. Asia-Pacific Live, Attenuated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  110. Asia-Pacific Inactivated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  111. Asia-Pacific Toxoid Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  112. Asia-Pacific Subunit vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  113. Asia-Pacific Conjugate vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  114. Asia-Pacific DNA vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  115. Asia-Pacific Recombinant vector vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  116. Asia-Pacific Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  117. Asia-Pacific Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  118. Asia-Pacific Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  119. Asia-Pacific Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  120. Asia-Pacific Pneumococcal Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  121. Asia-Pacific MMR Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  122. Asia-Pacific Varicella Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  123. Asia-Pacific Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  124. Asia-Pacific Poliovirus Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  125. Asia-Pacific HIB Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  126. Asia-Pacific Other Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  127. Asia-Pacific Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  128. Asia-Pacific Influenza Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  129. Asia-Pacific Cervical Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  130. Asia-Pacific Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  131. Asia-Pacific Zoster Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  132. Asia-Pacific Other Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  133. China Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  134. China Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  135. India Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  136. India Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  137. Japan Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  138. Japan Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  139. South Korea Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  140. South Korea Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  141. China Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  142. India Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  143. Japan Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  144. South Korea Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  145. China Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  146. India Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  147. Japan Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  148. South Korea Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  149. Latin America Preventive Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  150. Latin America Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  151. Latin America Live, Attenuated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  152. Latin America Inactivated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  153. Latin America Toxoid Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  154. Latin America Subunit vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  155. Latin America Conjugate vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  156. Latin America DNA vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  157. Latin America Recombinant vector vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  158. Latin America Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  159. Latin America Pediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  160. Latin America Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  161. Latin America Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  162. Latin America Pneumococcal Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  163. Latin America MMR Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  164. Latin America Varicella Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  165. Latin America Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  166. Latin America Poliovirus Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  167. Latin America HIB Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  168. Latin America Other Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  169. Latin America Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  170. Latin America Influenza Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  171. Latin America Cervical Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  172. Latin America Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  173. Latin America Zoster Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  174. Latin America Other Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  175. Brazil Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  176. Brazil Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  177. Argentina Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  178. Argentina Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  179. Mexico Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  180. Mexico Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  181. Brazil Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  182. Argentina Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  183. Mexico Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  184. Brazil Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  185. Argentina Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  186. Mexico Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  187. Middle East & Africa Preventive Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  188. Middle East & Africa Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  189. Middle East & Africa Live, Attenuated Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  190. Middle East & Africa Inactivted Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  191. Middle East & Africa Toxoid Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  192. Middle East & Africa Subunit vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  193. Middle East & Africa Conjugate vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  194. Middle East & Africa DNA vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  195. Middle East & Africa Recombinant vector vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  196. Middle East & Africa Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  197. Middle East & Africa Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  198. Middle East & Africa Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  199. Middle East & Africa Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  200. Middle East & Africa Pneumococcal Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  201. Middle East & Africa MMR Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  202. Middle East & Africa Varicella Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  203. Middle East & Africa Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  204. Middle East & Africa Poliovirus Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  205. Middle East & Africa HIB Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  206. Middle East & Africa Other Paediatric Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  207. Middle East & Africa Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  208. Middle East & Africa Influenza Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  209. Middle East & Africa Cervical Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  210. Middle East & Africa Hepatitis Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  211. Middle East & Africa Zoster Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  212. Middle East & Africa Other  Adult Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  213. Middle East Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  214. Middle East Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  215. Africa Preventive Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  216. Africa Preventive Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  217. Middle East Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  218. Africa Paediatric Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  219. Middle East Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  220. Africa Adult Vaccines Market, By Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample